PainRelief.com Interview with:
Ashley Mahoney–
Vertex Spokesman

PainRelief.com: What is the background for this study? What are the main findings of the underlying studies?

Response: On January 30, 2025, the FDA approved JOURNAVX, a new medicine developed by Vertex Pharmaceuticals which represents the first new class of acute pain medicine in more than 20 years. In our clinical trials, which were the largest double blind, placebo-controlled trials ever conducted in acute pain, JOURNAVX was shown to be effective, safe and well-tolerated. It led to clinically meaningful reductions in pain that were rapid and sustained, acting faster than placebo with fewer side effects than an opioid comparator and in many cases even the placebo arm. Based on its MOA and clinical/pre-clinical data we’ve seen to date, we also know JOURNAVX is non-addictive. 

Given this combination of efficacy, safety and non-addictive potential, we expect JOURNAVX to become the first line prescription medicine for the treatment of moderate-to-severe acute pain. We’re excited to bring this medicine to patients and expect JOURNAVX will be on shelves in retail pharmacies within a month.

Last Updated on January 31, 2025 by PainRelief.com